Clinical Trials

    Showing 1 - 10 of 16 Blood and Lymph Conditions

    Status: Enrolling

    Investigator: Shilpan Shah

    Study Coordinator: Danielle Sewall

    Phone: 346.238.2674

    The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2D[s]) of bleximenib in phase 1 (Part 1 [Dose Escalation] and to determine the safety and tolerability at RP2D in Phase 1 Part 2 (Dose expansion). The purpose of the Phase 2... Read more >

    Status: Enrolling

    Investigator: Siddhartha Ganguly

    Study Coordinator: Danielle Sewall

    Phone: 346.238.2674

    The goal of this study (iMMagine-3) is to compare the study drug, anitocabtagene autoleucel to standard of care therapy (SOCT) in participants with relapsed/refractory multiple myeloma who have received 1 to 3 prior lines of therapy, including an ant... Read more >

    Status: Open Not Enrolling

    Investigator: Siddhartha Ganguly

    Study Coordinator: Danielle Sewall

    Phone: 346.238.2674

    The purpose of the study is to compare the efficacy of talquetamab subcutaneous(ly) (SC) in combination with daratumumab SC and pomalidomide (Tal-DP) and talquetamab SC in combination with daratumumab SC (Tal-D), respectively, with daratumumab in com... Read more >

    Status: Open Not Enrolling

    Investigator: Siddhartha Ganguly

    Study Coordinator: Danielle Sewall

    Phone: 346.238.2674

    The purpose of this study is to compare the effectiveness of either talquetamab plus pomalidomide (Tal-P) or talquetamab plus teclistamab (Tal-Tec) with elotuzumab, pomalidomide, and dexamethasone (EPd) or pomalidomide, bortezomib, and dexamethasone ... Read more >

    Status: Enrolling

    Investigator: Sai ravi kiran Pingali

    Study Coordinator: Danielle Sewall

    Phone: 346.238.2674

    This is a global Phase 2, open-label, single-arm, multicohort, multicenter study to evaluate efficacy and safety of JCAR017 in adult subjects with r/r FL or MZL.... Read more >

    Status: Open Not Enrolling

    Investigator: Sai ravi kiran Pingali

    Study Coordinator:

    Phone:

    NCT049747319 Brief Summary: This study will evaluate the efficacy, safety, and pharmacokinetics of tirabrutinib monotherapy in patients with relapsed or refractory PCNSL (Part A), and tirabrutinib in combination with one of two different high dose ... Read more >

    Status: Open Not Enrolling

    Investigator: Shilpan Shah

    Study Coordinator: Danielle Sewall

    Phone: 346.238.2674

    This will be a multicenter Phase II open-label study of asciminib in CML-CP patients who have been previously treated with one prior ATP- binding site TKI with discontinuation due to treatment failure, warning or intolerance. (2L patient cohort). In ... Read more >

    Status: Enrolling

    Investigator: Carrie Yuen

    Study Coordinator: Danielle Sewall

    Phone: 346.238.2674

    This phase III trial compares the effect of adding a stem cell transplant with melphalan after completing chemotherapy with daratumumab, cyclophosphamide, bortezomib and dexamethasone (Dara-VCD) versus chemotherapy with Dara-VCD alone for treating pa... Read more >

    Status: Enrolling

    Investigator: Siddhartha Ganguly

    Study Coordinator: Danielle Sewall

    Phone: 346.238.2674

    This phase II trial compares iberdomide maintenance therapy to disease monitoring for improving survival in patients who have received idecabtagene vicleucel (a type of chimeric antigen receptor T-cell [CAR-T] therapy) for multiple myeloma. The usual... Read more >

    Status: Enrolling

    Investigator: Ross Reul

    Study Coordinator: Deena Victor

    Phone: 713.441.4536

    This trial is a prospective, randomized, multicenter, multinational, blinded, superiority trial. The objective of this trial is to evaluate the effectiveness of left atrial appendage exclusion (LAAE) for the prevention of ischemic stroke or systemic ... Read more >

    Status: Enrolling

    Investigator: Siddhartha Ganguly

    Study Coordinator: Danielle Sewall

    Phone: 346.238.2674

    The purpose of this study is to learn about the study medicine called elranatamab.This study aims to compare elranatamab to other medicines for the treatment of MM (a type of cancer).... Read more >

    Status: Open Not Enrolling

    Investigator: Siddhartha Ganguly

    Study Coordinator: Danielle Sewall

    Phone: 346.238.2674

    A phase 1b/2, open label, multi-center, Clinical Study of Chimeric Antigen Receptor T Cells targeting BCMA in patients with relapsed and or refractory multiple myeloma.... Read more >

    Status: Enrolling

    Investigator: Sai ravi kiran Pingali

    Study Coordinator: Milan Sheth

    Phone: 713.790.3311

    This is a Phase IB/II trial that will investigate the safety, tolerability and efficacy of combination therapy using All-Trans Retinoic Acid (ATRA) with Carfilzomib based therapies in plasma cell myeloma also commonly referred as Multiple Myeloma (MM... Read more >

    Status: Open Not Enrolling

    Investigator: Sai ravi kiran Pingali

    Study Coordinator: Natolie Hamilton

    Phone: 469.267.9275

    This is a laboratory-based study supported by NIH funding. It is aimed to explore the therapeutic effects of novel molecules or antigens to treat hematologic diseases. In order to complete these studies, samples including peripheral blood, bone marro... Read more >

    Status: Enrolling

    Investigator: Shilpan Shah

    Study Coordinator: Danielle Sewall

    Phone: 346.238.2674

    This phase III trial compares the effect of usual treatment of chemotherapy and steroids and a tyrosine kinase inhibitor (TKI) to the same treatment plus blinatumomab. Blinatumomab is a Bi-specific T-Cell Engager ('BiTE') that may interfere with the ... Read more >

    Status: Open Not Enrolling

    Investigator: Lawrence Rice

    Study Coordinator: Melissa Whipple

    Phone: 713.441.3247

    Paroxysmal nocturnal hemoglobinuria (PNH) is a rare condition. Prospective longitudinal data in large populations are limited. The aim of this International PNH Interest Group (IPIG) registry is to develop an international database to prospectivel... Read more >